An Open-label, Dose-escalation and Multi-center Study to Evaluate the Safety, Pharmacokinetics and Efficacy of SAR650984 (Isatuximab) in Patients With Relapsed/Refractory Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 15 Jan 2018
At a glance
- Drugs Isatuximab (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sanofi
- 10 Jan 2018 Planned End Date changed from 22 Jun 2020 to 2 Dec 2020.
- 10 Jan 2018 Planned primary completion date changed from 22 Jun 2020 to 21 Dec 2020.
- 12 Dec 2017 Results (n=4) assessing immune response, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.